Company Overview of Aridis Pharmaceuticals Inc.
Aridis Pharmaceuticals Inc., a biopharmaceutical company, develops anti-infective product candidates. The company offers AR-301, an anti-Staphylococcus aureus human monoclonal antibody to treat acute pneumonia; AR-101 and AR-104 that are specific lgM monoclonal antibodies, which target pseudomonas aeruginosa; and Aerucin, a broadly reactive monoclonal antibody against Pseudomonas aeruginosa. It also provides Panaecin, a small molecule anti-infective gallium compound with broad spectrum activities against bacteria, viruses, and fungi; AR201, a human monoclonal antibody, which treats respiratory syncytial virus infections; and AR401, a human monoclonal antibody for the treatment of Nosocomial ...
5941 Optical Court
San Jose, CA 95138
Founded in 2003
Key Executives for Aridis Pharmaceuticals Inc.
Co-Founder, Chief Executive Officer and Director
Co-Founder, Chairman and President
Compensation as of Fiscal Year 2014.
Aridis Pharmaceuticals Inc. Key Developments
Aridis Pharmaceuticals Inc. Appoints Craig Gibbs to Board of Directors
Apr 9 15
Aridis Pharmaceuticals Inc. announced the appointment of former Gilead Sciences executive Craig Gibbs, Ph.D., MBA, to its Board of Directors. Dr. Gibbs currently serves on the Board of Directors of Tobira Therapeutics and is an advisor to several biotechnology companies and venture capital firms.
Aridis Pharmaceuticals Commences Phase 1 Clinical Study of Aerucin™ Monoclonal Antibody for Acute Pneumonia
Mar 26 15
Aridis Pharmaceuticals Inc. announced the initiation of a Phase 1 clinical study of Aerucin™, the Company's fully human IgG1 monoclonal antibody (mAb) against Pseudomonas aeruginosa bacteria, which is being developed as an adjunctive treatment for acute pneumonia. Aerucin has also filed for Orphan Disease Designation with the U.S. Food and Drug Administration in the United States and in Europe. The clinical trial, expected to complete in the third quarter of 2015, is a Phase 1 single ascending dose study in healthy volunteers. Advancing to this stage of development represents the culmination of longstanding collaborations with Harvard University and the National Institutes of Health. Aerucin directly binds the alginate polysaccharide on the cell surface of P. aeruginosa. It was discovered using Aridis' proprietary MabIgX® technology by screening human B-cells for antibodies that demonstrated improved immune recognition and phagocytic destruction of more than 90% of all Pseudomonas aeruginosa. Earlier preclinical studies of Aerucin support both therapeutic and prophylactic use of the monoclonal antibody.
Aridis Pharmaceuticals Inc. Appoints Paul-Andre de Lame as Chief Medical Officer
Mar 23 15
Aridis Pharmaceuticals Inc. announced the appointment of Paul-Andre de Lame, M.D., as the company's Chief Medical Officer. Dr. de Lame founded Anabase International Corp. and was a co-founder and Chief Medical Officer of Cardiokine Inc.
Similar Private Companies By Industry
Recent Private Companies Transactions
September 18, 2014
May 31, 2014
Most Searched Private Companies
Sponsored Financial Commentaries